PMID- 11332147
OWN - NLM
STAT- MEDLINE
DCOM- 20010920
LR  - 20220321
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 12
IP  - 3
DP  - 2001 Mar
TI  - CHOP followed by involved field radiation: is it optimal for localized nasal 
      natural killer/T-cell lymphoma?
PG  - 349-52
AB  - The present study aimed to analyse the treatment outcome of four cycles of CHOP 
      (cyclophosphamide-vincristine-doxorubicin-prednisolone) followed by involved 
      field radiation therapy (IF RT) for the treatment of stage I-II nasal natural 
      killer (NK)/T-cell lymphoma. From March 1995 to December 1999, 17 patients 
      (median age 41 years; range 30-66) with localized nasal NK/T-cell lymphoma were 
      enrolled. B symptoms were noted in five patients (31%). Sixteen of seventeen 
      patients (94%) were of low risk when classified according to the International 
      Prognostic Index (IPI). The treatment plan consisted of four cycles of CHOP 
      chemotherapy followed by IF RT of 45 Gy. Two patients received radiation during 
      the first or second cycle of CHOP because of bleeding from the primary tumour 
      site. Both patients achieved complete responses (CRs). In the remaining 15 
      patients, after 4 cycles of CHOP, 6 CRs and 3 partial responses (PRs) were 
      achieved (53% of response rate). IF RT was given to six patients (four in CR, one 
      in PR and one in PD), and all six patients achieved CR. Overall, CR was achieved 
      in 10 of 17 patients (58%). The planned sequential chemoradiotherapy was 
      completed in only 6 of 17 patients (35%) because of the progression during 
      chemotherapy. None of the patients who achieved CR experienced relapse of 
      lymphoma during follow-up. The estimated overall three-year survival rate was 
      59%. In univariate analysis, B symptoms and stage were significant prognostic 
      factors for response and overall survival (P < 0.05). The present study suggests 
      that four cycles of CHOP followed by IF RT is not satisfactory for treating 
      patients with localized nasal NK/T-cell lymphoma, and that further exploration 
      for improved therapy is needed.
FAU - Kim, W S
AU  - Kim WS
AD  - Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Kangnam-Ku, Seoul, Korea.
FAU - Song, S Y
AU  - Song SY
FAU - Ahn, Y C
AU  - Ahn YC
FAU - Ko, Y H
AU  - Ko YH
FAU - Baek, C H
AU  - Baek CH
FAU - Kim, D Y
AU  - Kim DY
FAU - Yoon, S S
AU  - Yoon SS
FAU - Lee, H G
AU  - Lee HG
FAU - Kang, W K
AU  - Kang WK
FAU - Lee, H J
AU  - Lee HJ
FAU - Park, C H
AU  - Park CH
FAU - Park, K
AU  - Park K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cyclophosphamide/*therapeutic use
MH  - Disease-Free Survival
MH  - Doxorubicin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Lymphoma, T-Cell/*drug therapy/mortality/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Nose Neoplasms/*drug therapy/mortality/*radiotherapy
MH  - Prednisone/*therapeutic use
MH  - Radiotherapy Dosage
MH  - Radiotherapy, Adjuvant
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Vincristine/*therapeutic use
EDAT- 2001/05/03 10:00
MHDA- 2001/09/21 10:01
CRDT- 2001/05/03 10:00
PHST- 2001/05/03 10:00 [pubmed]
PHST- 2001/09/21 10:01 [medline]
PHST- 2001/05/03 10:00 [entrez]
AID - S0923-7534(19)54037-6 [pii]
AID - 10.1023/a:1011144911781 [doi]
PST - ppublish
SO  - Ann Oncol. 2001 Mar;12(3):349-52. doi: 10.1023/a:1011144911781.